Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of prostate adenocarcinoma.~* Patient must have progressive metastatic prostate cancer despite adequate medical or surgical castration therapy.~* Serum testosterone \< 50 mg/ml.~* Patients who have previously received docetaxel must meet BOTH of the the following criteria:~  * reason for docetaxel discontinuation must NOT have been progression of disease while receiving drug (i.e. progression of cancer must have been AFTER docetaxel discontinuation) AND~ * All docetaxel-related toxicities must have resolved to \< grade 1 (with the exception of alopecia) and the pt must be eligible by other criteria~Exclusion Criteria:~* Use of red blood cell or platelet transfusions within 4 weeks of treatment.~* Use of hematopoietic growth factors within 4 weeks of treatment.-Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.~* Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton (superscan).~* Prior radiation therapy encompassing \>25% of skeleton.Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).~* Platelet count \<150,000/mm3.~* Absolute neutrophil count (ANC) \<2,000/mm3.~* Hematocrit \<30 percent or Hemoglobin \< 10 g/dL.~* Abnormal coagulation profile (PT or INR, PTT) \> 1.3 x upper limit of normal (unless on therapeutic anticoagulation).~* -Serum creatinine \>2.5 mg/dL.~* AST (SGOT) \>2.5x ULN.~* Bilirubin (total) \>1.5x ULN.~* Serum calcium \>11 mg/dL.~* Active serious infection.~* Active angina pectoris or New York Heart Association Class III-IV.~* ECOG Performance Status \>2.~* Life expectancy \<6 months.~* Deep vein thrombosis and/or pulmonary embolus within 1 month of study entry.~* Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.~* Prior anti-PSMA monoclonal antibody therapy with the exception of ProstaScint®.~* Prior investigational therapy within 6 weeks of treatment.~* Known history of HIV.~* Known history of myelodysplastic syndrome or leukemia

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level 1 (Type: EXPERIMENTAL): 177Lu-J591 at 20 mCi/dose
- Dose Level 2 (Type: EXPERIMENTAL): 177Lu-J591 at 25 mCi/dose
- Dose Level 3 (Type: EXPERIMENTAL): 177Lu-J591 at 30 mCi/dose
- Dose Level 4 (Type: EXPERIMENTAL): 177Lu-J591 at 35 mCi/dose
- Dose Level 5 (Type: EXPERIMENTAL): 177Lu-J591 at 40 mCi/dose

Based on this trial design, predict the completion outcome and termination type (if applicable).